Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
13:473–475 © 1996 Lippincott–Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology Volume 13, 1996

Author Index

Aaby P, 355
Abramson PR, 456
Achenbach C, 416
Addiego JE, 78
Aledort LM, 78
Alvarez-Cañas C, 467
Amlee P, 392
Ammassari A, 294
Andersen RM, 327
Anderson J, 343
Andrieru JM, 55
Andrulis D, 416
Antinori A, 294
Arno P, 416
Arrastia C, 343
Artenstein AW, 392
Astemborski J, 267
Atkinson JS, 169
Audoly G, 468

Bacchetti P, 363
Baier-Bitterlich G, 184
Bandecchi P, 94
Barber CG, 422
Barin F, 468
Barron LE, 78
Bass DC, 78
Bassett MT, 287
Bassiakos Y, 235
Belle SH, 78
Bendtzen K, 93
Bennett CL, 408, 416
Bennett R, 416
Bera O, 468
Bessen L, 343
Bianco N, 281
Bizzini B, 55
Blazevic V, 208
Bofill M, 262
Boisson E, 434
Booth DK, 235
Borczuk AC, 48
Boyer P, 343
Brandt CD, 254
Brettler DB, 78
Briqnac H, 96
Brod-Miller C, 368
Brown M, 140
Brun-Pascaud M, 201
Bryant JL, 194
Buchanan GR, 78
Bürgisser P, 39
Burns DN, 374
Burny A, 55
Bush CE, 23
Buzelay L, 468

Calabró ML, 384
Cameron DW, 27
Camilo E, 155
Capps L, 374
Carr A, 320
Carr JK, 392
Carrigan DR, 97
Celentano D, 273
Cello JP, 348
Cesaire R, 468
Chams V, 55
Chang L-J, 101
Chau F, 201
Chiasson MA, 427
Chieco-Bianchi L, 384
Clark RA, 343
Clax PA, 235
Cloyd MW, 117
Cohn SE, 343, 408
Comar M, 462
Concepcion L, 48
Connor JD, 235
Cooney E, 235
Cooper DA, 320
Cosler L, 227
Craddock BP, 18
Criscuolo M, 55
Crumpacker CS, 235
Cruz E, 155
Cunningham WE, 327
Curtis JR, 416
Cusini M, 55

Damiano F, 294
Datta S, 440
Dayton AI, 403
De Clercq E, 127
De Paoli P, 462
de Perez GE, 281
de Souza M, 392
Dega H, 146
DeHovitz JA, 408
Denning P, 98
Deo YM, 117
Derouin F, 201
Desgranges C, 468
Desmyter J, 127
Detels R, 448
Diamant M, 93
Dias F, 355
Dickie P, 101
Dickinson GM, 408
Donovan RM, 23
Dorsky DI, 308
Duerstein SL, 78
Dupont B, 146

Edlin BR, 87
Eichberg JW, 12
Elford J, 262
Eliaszewicz M, 146
Ellaurie M, 254
Emery S, 320
Epple H-J, 33
Erice A, 235
Eschevarria S, 467
Espinal MA, 155
Essex M, 299
Ewenstein BM, 78

Factor SM, 48
Fahs MC, 416
Fall L-S, 55
Fantoni M, 294
Farinotti R, 201
Faruque S, 87
Farzadegan H, 448
Favero A, 384
Feldman M, 55
Ferrante P, 384
Ferrazoli L, 177
Ferreira MMC, 177
Ferreira OC Jr, 177
Fillion D, 27
Fillon S, 468
Flammand L, 194
Fleury J, 146

Franciotta D, 12
Frank I, 247
Fredrickson T, 101
Fuchs D, 184
Furlan R, 12
Fyke K, 27

Gallo RC, 194
Garcia-Sáiz A, 384
Garry L, 201
Gaywee J, 392
Gessain A, 397
Giacca M, 462
Gill JC, 78
Girard P-M, 201
Gisselbrecht M, 146
Gleghorn A, 267
Gobbers E, 127
Gonzalez G, 155
Gonzalez-Canali G, 146
González-Lahoz J, 384
Gordin FM, 374
Gotzsche PC, 93
Goubau P, 127
Green D, 78
Greenberg PD, 348
Greenblatt R, 343
Griffith BP, 235
Grimaldi LME, 12
Gringeri A, 55

Halloran ME, 440
Harrington D, 97
Harrington RD, 308
Hawley-Foss N, 27
Hays RD, 327
Heino M, 208
Heise W, 33
Henrard DR, 448
Heredia A, 384
Hermans P, 55
Herndier BG, 215
Hewlett IK, 384
Hilgartner MW, 78
Hillman D, 374
Hogg R, 422
Holden-Wiltse J, 235
Hoots WK, 78
Horner RD, 416
Houchens R, 227
Hu Y, 98
Hussey S, 235

Ignatius R, 33
Ittiravivongs A, 296

Jaans A, 247
Jaffe R, 78
Janossy G, 262
Janssen B, 146
Japour AJ, 235
Jarvik JG, 247
Jiang S, 461
Johanneson N, 235
Johnson WD, 177

Katzenstein DA, 287
Kaufman TE, 254
Kelleher A, 320
Keller T, 117
Kessler HA, 408
Kiefer CR, 177
Kingsley LA, 78
Kirby AJ, 448
Kisker CT, 78
Kitayaporn D, 296
Kleeberger CA, 448
Klein JD, 408
Knox KK, 97
Knudsen K, 355
Kok W, 127
Komanduri KV, 215
Kravcik S, 27
Kritski AL, 177
Krohn KJE, 208
Kvale P, 23

Lachgar A, 55
Lagerstedt A, 208
Lake-Bakaar G, 295
Larsen SA, 87
Latkin C, 273
Law M, 320
Lee CA, 262
Lenkinski RE, 247
Leon-Ponte M, 281
Lertora JJ, 235
Li H, 117
Li Y-Y, 461
Liesenfeld O, 33
Likanonsakul S, 296
Limpakarnjanarat K, 296
Lin J-C, 1
Lin K, 461
Lisse IM, 355
Locker J, 78
Longini IM Jr, 440
Lorenzo E, 140
Lovrien EW, 78
Lu W, 55
Luce JA, 215
Lunardi-Iskandar Y, 194

Machekano R, 287
Malvaldi G, 94
Mancuso R, 384
Mandell W, 273
Mannella E, 384
Mannucci PM, 55
Mar E-C, 1
Margolick JB, 448
Marinoni A, 55
Markowitz GS, 48
Markowitz LE, 392
Markowitz MP, 23
Markson LE, 227
Martin MA, 101
Martino G, 12
Mastro TD, 296
Matos N, 155
Matsuura S, 140
Mattana J, 368
Mbika JP, 55
Mbizvo MT, 287
McCoy CB, 87
McCutchan FE, 392
McFarland WC, 287
McGrath MS, 215
McLaren C, 235
Medeiros LA, 177
Medford RM, 1
Meehan PM, 235
Meylan PRA, 39
Michael R, 392
Miller G, 101
Miller LK, 96
Mitchell T, 374
Montaner JSG, 422
Montoya ID, 169
Moore J, 267
Moorjani H, 18
Morrison SA, 18
Mosen DM, 327
Mounts P, 101
Moyle GJ, 464
Muça-Perja M, 55
Mueller N, 427
Murphy C, 422
Murri R, 294
Murthy KK, 12
Musicco M, 55
Muto J, 98

Naiwatanakul T, 296
Nasti G, 462
Natanjo A, 467
Neaton JD, 374
Neisson-Vernant C, 468
Neurath AR, 461
Ng VL, 215
Nicoll A, 434
Nittayaphan S, 392
Novoa P, 177
Noya O, 281

O'Donnell RM, 254
Offermann MK, 1
O'Gorman M, 448
Olson PE, 96
O'Shaughnessy M, 422
Ouka M, 468
Oziemkowska M, 273

Pagano M, 427
Palaci M, 177
Pancake BA, 314

Paolicchi A, 94
Pedersen BK, 93
Peetermans W, 127
Pérez G, 155
Perinbasekar S, 368
Phair JP, 448
Phillips AN, 262
Phillips P, 422
Pialoux G, 146
Pinkerton SD, 456
Pollard R, 235
Poulsen A-G, 355
Purcell D, 101

Rabkin JG, 465
Rabkin R, 465
Ragni MV, 78, 160
Rakusan TA, 254
Ranki A, 208
Ray S, 287
Reingold AL, 155
Renjifo B, 299
Riecken E-O, 33
Riley LW, 177
Rinaldo CR Jr, 448
Rodrigue DC, 408
Rodrigues LC, 434
Rutherford CJ, 78

Saah AJ, 448
Sabin CA, 262
Saint-Martin L de, 146
Salles PS, 177
Saltzman BR, 336
Sanders NL, 78
Sanjudn JCR, 467
Santagostino E, 55
Saravolatz LD, 23
Sathyavagiswaran L, 98
Saxena ES, 254
Saykin AJ, 247
Schechter MT, 422
Schechtmann M, 177
Schmid DS, 87
Schmidt W, 33
Schmit J-C, 127
Schneider T, 33
Schrager L, 448
Schuman P, 343
Scoppettuolo G, 294
Scott G, 140
Scott W, 140
Serrano Y, 87
Sever JL, 254
Shapiro MF, 327, 408
Shaw R, 1
Shaw-Taylor Y, 416
Shen D, 295
Sherer R, 374
Shevitz A, 427
Silva S, 94
Silverman NS, 227
Simon P, 98
Simonelli C, 462
Sison AV, 254
Skinhoj P, 93
Smith KJ, 78
Smith L, 140
Solomon L, 267
Sorbi D, 295
Soriano V, 384
Soto S, 155
Soto-Ramirez LE, 299
Spertini F, 39
Srour LF, 422
Stabler SP, 78
Steigbigel RT, 18
Stöffler-Meilicke M, 33
Strick N, 461
Sukchamnong A, 392
Swindells S, 78, 343

Takyi BK, 227
Tansuphasawadikul S, 296
Taylor E, 448
Taylor GP, 68
Teich SA, 336
Thé G de, 397
Thomas P, 427
Thurnherr MD, 374
Till M, 343
Timms A, 262
Timpone J, 235
Tirelli U, 462
Tonarelli P, 94
Toye BW, 27
Trichavaroj R, 392
Tripathy S, 299
Turner BJ, 227

Ullrich R, 33
Ullum H, 93
Ünal A, 140

Vaccher E, 462
Vallejo A, 384
Vallier WG, 374
van de Wijgert JHHM, 287
Van Dooren S, 127
Van Laethem K, 127
VanCott TC, 392
Vandamme A-M, 127
Victor J, 93
Vitale LA, 117
Vlahov D, 267, 273
Vogler M, 343
Von Bargen JC, 87

Wachter H, 184
Wagner GJ, 465
Walesky M, 235
Wallace MR, 96
Watts DH, 343
Weinke T, 33
Weinstein RA, 408
Weissfeld JL, 160
Wells M, 308
Weyrich-Suter C, 39
White GC III, 78
Witvrouw M, 127
Wood K, 235
Word CO, 87

Yang J, 1
Young M, 343
Young N, 296
Yurack JA, 27

Zaba B, 434
Zagury D, 55
Zagury JF, 55
Zanussi S, 462
Zeitz M, 33
Zeman RA, 194
Zhang MJ, 403
Zucker-Franklin D, 314

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
13:476–480 © 1996 Lippincott–Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology Volume 13, 1996

Subject Index

Abscess, *Pasteurella pneumotropica*-induced, 101
Access to care
  expanded, 422
  for HIV patients, 327
Adenovirus, in HIV-infected patients, 33
Adolescence, AIDS and, 427
Africa
  HTLV-II in, 397
  risk factors for HIV infection in male factory workers in, 287
AIDS. *See also* HIV infection; HIV-1 infection
  access to care for, 327
  autopsy patterns among subgroups of, 48
  with bacterial pneumonia, 23
  central nervous system involvement in, 12
  clinical trial, for anti-interferon-à immunization, 55
  definition change for, 363
  geographic variation in management and outcomes of *Pneumocystis carinii* pneumonia in, 408
  HHV-6A in pathogenesis of, 97
  hospital care for in U.S., 416
  impact on hemophilia birth cohorts, 160
  neopterin and 7,8-dihydroneopterin in, 184
  reporting delays of deaths with, 363
  self-screening chart for cytomegalovirus retinitis in, 336
  smoking and clinical outcome of, 374
  stool viruses, coinfections, and diarrhea in, 33
  TIVAD-associated infections in, 146
  treatment of severe diarrhea with, 348
  virologic and serologic markers of rapid progression to, 448
  in women and heterosexual men, 427
AIDS-associated non-Hodgkin's lymphoma, in hemophiliacs, 78
Amerindians, HTLV-II among, 281
AMPLICOR HIV monitor test, results of, 127
Anemia, transfusions-requiring, mycobacterial infections in, 27
Antibody-dependent cellular cytotoxicity, 117
Anticytokine vaccination, for AIDS, 55
Anti-gag immune response, in rapid progression to AIDS, 448
Anti-interferon-α immunization, clinical trial on, 55
Antiretroviral agents
  CD8+ lymphocytes responses to, 320
  open-arm clinical trials of, 422
Aphthous ulcers, in HIV-infected women, 343
Apoptosis, in HIV progression, 184
Autopsy patterns, of inner-city AIDS subgroups, 48
AZT. *See* Zidovudine

Behavioral settings, needle sharing among drug users and, 273
Bernoulli model, for estimating risk reduction with occasional condom use, 456
Blood transfusion
  HTLV transmission through, 68
  HTLV-II subtypes in donors for, 384
Bovine immunoglobulins
  β-lactoglobulin, blocking HIV-1 uptake, 461
  for severe diarrhea with *Cryptosporidium parvum* infection, 348
Brazil, tuberculosis and HIV infection in female inmates of, 177

Catheter, infections associated with, 146
CD38 expression, in HIV-associated malignant lymphoma, 215
CD4 lymphocytes
  in HIV seroconversion, 262
  modulation for HIV antibody, 117
  mortality and counts of, 355
  in phagosome-lysosome fusion, 18
CD8 lymphocytes
  in antiretroviral therapy, 320
  mortality and counts of, 355
Cellular adhesion molecules, in antioxidant-sensitive regulation of inflammatory-response genes, 1
Central nervous system, in HIV-1 infection, 12
Cerebrospinal fluid, immunovirological study of in HIV-1 infection, 12
Children
  HIV DNA blood levels in, 254
  HIV infection with tuberculosis in, 155
  zidovudine treatment in, 140
Cigarette smoking, HIV-1 infection outcome and, 374
Clinical progression, in children treated with zidovudine, 140
Clinical trials
  community-based, open-arm, randomized, 422
  of vaccine efficacy, 440
Cohort study
  of asymptomatic HIV-infected adults, 247
  of tuberculosis and HIV infection in female inmates, 177
Coinfections
  HIV-1 subtypes B and F in, 468
  in HIV-infected patients, 33
  trimethoprim-sulfamethoxazole ratios for, 201
Combination therapy, open-arm clinical trials of, 422
Community-based medical services, access to, 327
Condoms, in HIV risk reduction, 456
Coronavirus, in HIV-infected patients, 33

Coroner's data, in monitoring HIV seroprevalence in drug users, 98
Counseling, in high-risk inner-city women, 267
Crack cocaine
  HIV seroprevalence rates and, 169
  oral sores and, 87
Cryptosporidium parvum infection, severe diarrhea with, 348
Cytokines. *See also specific types*
  in antioxidant-sensitive regulation of inflammatory-response genes, 1
  in CNS during HIV-1 infection, 12
  in immune function in HIV-1 infection, 208
Cytomegalovirus
  in AIDS autopsies, 48
  retinitis, self-screening chart for, 336

ddC, lymphoma occurrence with, 464
Demographic model, of HIV in hemophilia, 160
Diarrhea
  in HIV-infected patients, 33
  treatment for in *Cryptosporidium parvum* infection, 348
Didanosine
  open-arm clinical trials of, 422
  with ribavirin, safety, pharmacokinetics, and antiviral activity of, 235
7,8-Dihydroneopterin, in HIV infection, 184
Disease progression
  with anti-interferon-α immunization, 55
  with cigarette smoking, 374
  markers for, 184
  virologic and serologic markers of, 448
DNA quantitation, for vertically infected pediatric patients, 254
Drug users
  anti-HCV antibody titers of, 295
  HIV seroprevalence rates in, 98, 169
  HTLV-II subtypes in, 384
  needle sharing among, 273

Edema, in HIV-infected patients with end-stage renal disease, 368
End-stage renal disease, with HIV infection, 368
  env sequences, in HIV-1 subtype, 299
Epidemiology
  for AIDS in women and heterosexual men, 427
  of HIV infection in hemophilia birth cohorts, 160
Epithelial cells, bovine β-lactoglobulin preventing uptake of HIV-1 by, 461
Epstein-Barr virus, malignant lymphomatous effusions in, 215
Erratum: What is the situation of human T cell lymphotropic virus type II (HTLV-II) in Africa. A. Gessain, G de Thé:13(Suppl 1):S228-S235, 1996, 397
Europe
  HTLV seroepidemiology in, 68
  nucleotide sequence and RFLP analysis of HTLV-II in, 384

Feline immunodeficiency virus, glutathione metabolism in, 94
Female inmates, tuberculosis and HIV infection among, 177
Fertility risk, HIV seroprevalence data on, 434
Fine needle aspiration, of lymph nodes, 39

Gastric lymphoma, in HIV infection, 467
Gastroenteritis, viral, in HIV-infected patients, 33
Genetics, in HIV-1 subtyping, 392
Genital ulcers, in HIV-infected women, 343
Geographic distribution, of HIV seroprevalence, 169
Global health status, Karnofsky Performance Status in assessing, 294
Glutathione, metabolism during FIV infection, 94
gp160, HIV-1, 117
gp120, in phagosome-lysosome fusion, 18
Green fluorescent protein reporter system, in detecting HIV-1 infection, 308
Guinea-Bissau, morality associated with serial T-lymphocyte counts in, 355

HCV antibody titers, for intravenous drug users, 295
Health status, Karnofsky Performance Status in assessing, 294
Hemophilia
  AIDS-associated non-Hodgkin's lymphoma in, 78
  HIV infection impact on, 160
HHV. *See* Human herpesvirus
High-risk population, HIV testing and counseling in, 267
HIV envelope, development of T-cell line expressing, 117
HIV infection. *See also* AIDS; HIV-1 infection
  access to care for, 327
  CD8+ lymphocytes responses to antiretroviral therapy for, 320
  in children with tuberculosis, 155
  community-based, open-arm clinical trials of combination therapy for, 422
  condom use in risk reduction for, 456
  in crack cocaine smokers, 87
  DNA blood levels in pediatric patients, 254
  in end-stage renal disease, 368
  in female inmates, 177
  genital ulcers in women with, 343
  hospital care for in U.S., 416
  hydroxyurea treatments in, 462
  immunologic effects of psychotropic drugs for, 465
  immunovirological study of CNS involvement in, 12
  impact on size of future hemophilia and carrier birth cohorts, 160
  interleukin-6 circulating levels, 93
  interpreting seroprevalence data from pregnant women, 434
  maternal, low birth weight and, 227
  neopterin and 7,8-dihydroneopterin in, 184
  primary gastric lymphoma in, 467
  proton spectroscopy for, 247
  risk factors for urban male factory cohort, 287
  serial T-lymphocyte counts and mortality in, 355
  serodiagnosis of in high-risk inner-city women, 267
  in serum anti-HCV antibody titers, 295
  stavudine as salvage therapy in, 96
  stool viruses, coinfections, and diarrhea in, 33
  TIVAD-associated infections in, 146
  transmission in crack cocaine smokers, 87
HIV-1 infection. *See also* AIDS; HIV infection
  bovine β-lactoglobulin preventing uptake of, 461
  cigarette smoking and clinical outcomes in, 374
  didanosin-ribavirin for, 235
  green fluorescent protein reporter system in detecting, 308
  impairment phagosome-lysosome fusion in, 18
  interleukin-10 gene expression in, 208

HIV-1 infection *(contd.)*
lymphoma occurrence with ddC or ddC/zidovudine combination therapy for, 464
myopathy and spontaneous *Pasteurella pneumotropica*-induced abscess in, 101
reverse transcriptase mutations in, 140
RRE structures of, 403
subtypes B and F of, 468
subtyping, genetic and serologic approaches to, 392
HIV-1 *pol* sequences, subtype pattern of, 299
HIV replication, neopterin and, 184
HIV-1 reporter systems, 308
HIV-1 Rev, interleukin-10 gene expression induced by, 208
HIV RNA
quantification in plasma, 127
viral load in AIDS with bacterial pneumonia, 23
HIV-1 seroconversion
serum β2-microglobulin at, 262
virologic and serologic markers of rapid progression to AIDS after, 448
HIV seroprevalence
determinants among drug users, 169
in drug users, 98
interpreting data from pregnant women, 434
HIV-1 Tat, interleukin-10 gene expression induced by, 208
HIV testing
in high-risk inner-city women, 267
using Western blot, 296
HIV-1 vaccine, measuring efficacy of, 440
HIV-associated malignant effusions, natural history and molecular heterogeneity of, 215
Hospitalization, for HIV infection, 327
Hospitals, care of HIV-infected patient in, 416
HTLV. *See* Human T-cell lymphotropic virus
Human herpesvirus 8
DNA, absence in neoplastic Kaposi's sarcoma cell lines, 194
malignant lymphomatous effusions in, 215
Human herpesvirus 6A, in pathogenesis of AIDS, 97
Human immunodeficiency virus. *See* AIDS; HIV infection
Human T-cell leukemia/lymphoma virus, seroepidemiology of in Europe, 68
Human T-cell lymphotropic virus
type I
coinfection with HIV-1, 468
detecting proviral sequences in mycosis fungoides, 314
type II
in Africa, 397
in Amerindians, 281
nucleotide sequence and RFLP analysis of, 384
subtypes of, 384
Hydroxyurea, in HIV infection, 462
Hypoalbuminemia, in end-stage renal disease, 368

Immune response
envelope HIV glycoproteins in evaluation of, 117
interleukin-10 genes in, 208
to psychotropic drugs, 465
Immunization, AIDS, 55
Immunodeficiency, β_2-microglobulin predictor of, 262
Immunophenotype cells, from lymph nodes versus peripheral blood cells, 39
Immunotherapy, interferon-α in, 55
Immunovirology, of CNS in HIV-1 infection, 12
Incidence adjustment, with AIDS definition change, 363
India, HIV-1 *pol* sequences from, 299
Infants, HIV DNA blood levels in, 254
Infection, TIVAD-associated, 146
Inflammatory-response gene, antioxidant-sensitive regulation in Kaposi's sarcoma cells, 1
Injection drug users
anti-HCV antibody titers of, 295
HIV seroprevalence rates in, 169
HTLV-II subtypes in, 384
monitoring HIV seroprevalence in, 98
needle sharing among, 273
Interferon-α, as AIDS vaccine, 55
Interleukin-6, increased circulating level in HIV, 93
Interleukin-10 gene expression, in HIV-1 infection, 208
Isoelectric focusing overlay, in immunovirological study of CNS during HIV-1 infection, 12
Isoniazid, response in children with tuberculosis, 155
Italy, HTLV-II subtypes in, 384

Kaposi's sarcoma
antioxidant-sensitive regulation of inflammatory-response genes in, 1
HHV-8 DNA in, 194
Karnofsky Performance Status, validity of, 294

Letters to editor
changes of glutathione metabolism during feline immunodeficiency virus infection, 94
chemically modified bovine β-lactoglobulin blocks uptake of HIV-1 by colon- and cervix-derived epithelial cell lines, 461
clinical experience with stavudine as salvage therapy in patients with advanced HIV disease, 96
evaluation of a confirmatory HIV testing strategy in Thailand not using Western blot, 296
hydroxyurea treatments in HIV-infected patients, 462
immunologic effects of psychotropic drugs in HIV+ patients, 465
increased circulating levels of interleukin-6 in HIV-seropositive subjects, 93
influence of HIV disease on serum anti-HCV antibody titers: a study of intravenous drug users, 295
Karnofsky performance status and assessment of global health status, 294
occurrence of lymphomas during ddC or ddC/zidovudine combination therapy in persons infected with HIV type I, 464
presence of HIV-1 subtypes B and F and HTLV-I in HIV/HTLV coinfected individuals of Martinique, 468
primary gastric lymphoma in an HIV-infected patient, 467
use of coroner's data to monitor HIV seroprevalence among injection drug users, 98
variant A human herpesvirus 6 as cofactor in pathogenesis of AIDS, 97
Leu3a, in phagosome-lysosome fusion, 18
Low birth weight, maternal HIV infection and, 227
Lymph node, viral load and immunophenotype cells from, 39
Lymphoma
AIDS-associated non-Hodgkin's, 78

cutaneous T cell, 314
during ddC or ddC/zidovudine therapy, 464
HIV-associated malignant effusions of, 215
primary gastric in HIV-infected patient, 467
Lysosome, in HIV-1 infection, 18

Macrophage, impaired phagosome-lysosome fusion in, 18
Magnetic resonance spectroscopy, in HIV-infected adults, 247
Malignancy, HHV-8 DNA in, 194
Malignant effusion, HIV-associated lymphomatous, 215
Martinique, HIV-1 subtypes B and F in HIV/HTLV coinfection in, 468
Medicaid, HIV-infected mothers in, 227
β2-Microglobulin, as immunodeficiency predictor, 262
Mortality, regional variation in, 408
Mother-child HIV transmission, 227
HIV DNA blood levels with, 254
Mouse model, myopathy and *Pasteurella pneumotropica*-induced abscess in, 101
Mycobacterium avium complex, prophylaxis, impact of, 27
Mycobacterium tuberculosis infection, in female inmates, 177
Mycosis fungoides, HTLV-I proviral sequences in, 314
Myopathy, in HIV-1 transgenic mouse model, 101

NASBA HIV-1 RNA QT, results of, 127
Needle sharing, behavior and personal network characteristics as correlates of, 273
Neopterin, in HIV infection, 184
Nucleotide sequence, of HTLV-II in southern Europe, 384

Open-arm clinical trials, 422
Oral sex, in crack cocaine smokers, 87
Oral sores, in crack cocaine smokers, 87
Oxidation, in Kaposi's sarcoma cells, 1

Pasteurella pneumotropica-induced abscess, in HIV-1 transgenic mouse model, 101
Peripheral blood cells, viral load from, 39
Phagosome-lysosome fusion, impairment in HIV-1-infected macrophages, 18
Phase-1 drug study, of didanosin-ribavirin for HIV-1 infection, 235
Phase III study, for HIV-1 vaccine, 440
Phenotype assessment, from fine needle aspiration of lymph nodes, 39
Phylogenetic analysis, of HIV-1 *pol* sequences, 299
Physician practice patterns, for AIDS-related *P. carinii* pneumonia, 408
Pneumocystis carinii pneumonia
geographic variation in management and outcomes of, 408
hospital care for in U.S., 416
trimethoprim-sulfamethoxazole ratios for, 201
Pneumonia
in AIDS autopsies, 48
bacterial
HIV RNA viral load in, 23
smoking and clinical outcome of, 374
geographic variation in management and outcomes of AIDS-related, 408
pol sequences, in HIV-1 subtype, 299
Polymerase chain reaction (PCR)
in detecting HTLV-I proviral sequences, 314
for endemic HTLV-II infection, 281
typing in Thailand, 392
Pregnancy, HIV seroprevalence during, 434
Prevention, in high-risk inner-city women, 267
Prognosis, with antiretroviral therapy, 320
Proton spectroscopy, in asymptomatic HIV-infected adults, 247
Proviral sequence detection methods, 314
Psychotropic drugs, immunologic effects of, 465

Reactive oxygen intermediates, in HIV infection progression, 184
Redox sensitive gene expression, in Kaposi's sarcoma, 1
Regional variation, in AIDS management and outcomes, 408
Restriction fragment-length polymorphism analysis, of HTLV-II in southern Europe, 384
Rev protein, in HIV-1, 403
Reverse transcriptase mutation, with zidovudine treatment, 140
Ribavirin-didanosine, safety, pharmacokinetics, and antiviral activity of, 235
Rifabutin, in *Mycobacterium avium* complex prophylaxis, 27
Rifampicin, response in children with tuberculosis, 155
Risk
factors for, in urban male factory cohort, 287
reduction of, occasional condom use in, 456
RNA-PCR, in monitoring HIV-1 viral load, 127
RRE structure, in HIV-1, 403
RT-PCR, for interleukin-10 gene expression, 208

Salvage therapy, stavudine in, 96
Santo Domingo, HIV infection in children with tuberculosis in, 155
Screening
for cytomegalovirus retinitis, 336
for HTLV in Europe, 68
Self-screening chart, for cytomegalovirus retinitis, 336
Sepsis, TIVAD-associated, 146
Serial T-lymphocyte counts, morality and, 355
Seroepidemiology, of HTLVs in Europe, 68
Serologic marker, of rapid progression to AIDS, 448
Serology, in HIV-1 subtyping, 392
Serotyping, genetic and serologic approaches to, 392
Sexual behavior, in urban male factory cohort, 287
Sexual transmission, in crack cocaine smokers, 87
Sézary syndrome, HTLV-I proviral sequences in, 314
Smoking, HIV-1 disease progression and, 374
Social networks, needle sharing among drug users and, 273
Southern analysis, in detecting HTLV-I proviral sequences, 314
Spain, HTLV-II subtypes in, 384
Spectroscopy, in HIV-infected adults, 247
Stavudine, as salvage therapy in HIV infection, 96
Stool virus, in HIV-infected patients, 33
Sulfamethoxazole, for *Toxoplasma gondii* and *Pneumocystis carinii* coinfections, 201
Surrogate markers, for HIV RNA viral load in AIDS with bacterial pneumonia, 23
Surveillance, of deaths with AIDS in U.S., 363

T-cell line, envelope glycoprotein expression in, 117
T-cell lymphoma, cutaneous, 314
Thailand
genetic and serologic approaches to HIV-1 subtyping in, 392
HIV testing using Western blot in, 296

Totally implantable venous access devices (TIVAD), infections associated with, 146
Toxoplasma gondii infection, trimethoprim-sulfamethoxazole ratios for, 201
Transfusion, *Mycobacterium avium* complex prophylaxis in, 27
Transmission
in crack cocaine smokers, 87
of HTLV in Europe, 68
mother-child, 227
Trimethoprim-sulfamethoxazole, altered ratios for *Toxoplasma gondii* and *Pneumocystis carinii*, 201
Tuberculosis
in female inmates, 177
HIV infection with in children, 155

United States
hospital care for HIV-infected persons in, 416
reporting delays of deaths with AIDS in, 363

Vaccine, measuring efficacy of, 440
Venezuela, endemic HTLV-II in, 281
Venous access device, infections associated with, 146
Vertical transmission, HIV DNA blood levels in, 254
Veterans Administration hospitals, care of HIV-infected patient in, 416
Viral load
in AIDS with bacterial pneumonia, 23
with antiretroviral therapy, 320
from lymph nodes versus peripheral blood cells, 39
RNA-PCR monitoring of, 127
Virologic marker, of rapid progression to AIDS, 448
Virus isolation, in CNS during HIV-1 infection, 12
Visual fields, in cytomegalovirus retinitis, 336

Western blot, in HIV testing in Thailand, 296
Women
AIDS and, 427
genital ulcers in, 343
HIV seroprevalence in, 434
HIV testing behavior in high-risk population of, 267
inmates, tuberculosis and HIV infection in, 177
Workplace, risk factors for HIV infection in, 287

Zalcitabine, open-arm clinical trials of, 422
Zidovudine
clinical trials of, 422
in HIV-1 infected children, 140
lymphoma occurrence with, 464
Zimbabwe, risk factors for HIV infection in male factory workers in, 287



UNITED STATES POSTAL SERVICE

Statement of Ownership, Management, and Circulat
(Required by 39 USC

1. Publication Title: Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology
2. Publication Number: 1 0 7 7 - 9 4 5 0
3. Filing Date: October 1, 1996
4. Issue Frequency: 15 times a year
5. Number of Issues Published Annually: 15
6. Annual Subscription Pric: $178.00 US
7. Complete Mailing Address of Known Office of Publication (Not printer) (Street, city, county, state, and ZIP+4): Lippincott-Raven Publishers, 12107 Insurance Way, Hagerstown, MD 21740
Contact Person
Telephone
8. Complete Mailing Address of Headquarters or General Business Office of Publisher (Not printer): 227 East Washington Square, Philadelphia, PA 19106
9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do not leave blank)
Publisher (Name and complete mailing address): Lippincott-Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106
Editor (Name and complete mailing address): W. A. Haseltine, Human Genome Science Inc., 9620 Medical Center Dr, Rockville, MD 20850; F. A. Volberding, San Francisco General Hosp., AIDS Activity Div., San Francisco, CA 901; W. A. Blattner, Institute of Human Virology, Univ. of Maryland, Baltimore, MD 21201
Managing Editor (Name and complete mailing address): Greg Fagan, Lippincott-Raven Publishers, 1185 Ave of the AMERICAS, N.Y., N.Y. 10036
10. Owner (Do not leave blank. If the publication is owned by a corporation, give the name and address of the corporation immediately followed by the names and addresses of all stockholders owning or holding 1 percent or more of the total amount of stock. If not owned by a corporation, give the names and addresses of the individual owners. If owned by a partnership or other unincorporated firm, give its name and address as well as those o each individual owner. If the publication is published by a nonprofit organization, give its name and address.)

Full Name	Complete Mailing Address
Lippincott-Raven Publishers	227 East Washington Square, Phila., PA 1910
Wolters Kluwer US	1185 Avenue of the Americas, N.Y., N.Y. 1003
Wolters Kluwer nv (owns 100% of stock)	Stadouderskade 1 1054 ES Amsterdam, The Netherlands

11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities. If none, check box → ☐ None

Full Name	Complete Mailing Address
None	

12. Tax Status (For completion by nonprofit organizations authorized to mail at special rates) (Check one)
The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes:
☐ Has Not Changed During Preceding 12 Months
☐ Has Changed During Preceding 12 Months (Publisher must submit explanation of change with this statement)

13. Publication Title: Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology
14. Issue Date for Circulation Data Below: Vol. 13, #1

15. Extent and Nature of Circulation		Average No. Copies Each Issue During Preceding 12 Months	Actual No. Copies of Single Issue Published Nearest to Filing Da
a. Total Number of Copies (Net press run)		2,969	3,100
b. Paid and/or Requested Circulation	(1) Sales Through Dealers and Carriers, Street Vendors, and Counter Sales (Not mailed)	—	—
	(2) Paid or Requested Mail Subscriptions (Include advertiser's proof copies and exchange copies)	1,849	1,857
c. Total Paid and/or Requested Circulation (Sum of 15b(1) and 15b(2))	▶	1,849	1,857
d. Free Distribution by Mail (Samples, complimentary, and other free)		304	363
e. Free Distribution Outside the Mail (Carriers or other means)		—	—
f. Total Free Distribution (Sum of 15d and 15e)	▶	304	363
g. Total Distribution (Sum of 15c and 15f)	▶	2,153	2,220
h. Copies not Distributed	(1) Office Use, Leftovers, Spoiled	816	880
	(2) Returns from News Agents	—	—
i. Total (Sum of 15g, 15h(1), and 15h(2))	▶	2,969	3,100
Percent Paid and/or Requested Circulation (15c / 15g x 100)		86%	84%

16. Publication of Statement of Ownership
☐ Publication required. Will be printed in the Vol 13, #3 issue of this publication.
☐ Publication not required.
17. Signature and Title of Editor, Publisher, Business Manager, or Owner: Beverly V. Dietrich Circulation Director — Date: 9/26/96
I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information requested on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including multiple damages and civil penalties).

Instructions to Publishers

1. Complete and file one copy of this form with your postmaster annually on or before October 1. Keep a copy of the completed form for your records.
2. In cases where the stockholder or security holder is a trustee, include in items 10 and 11 the name of the person or corporation for whom the trustee is acting. Also include the names and addresses of individuals who are stockholders who own or hold 1 percent or more of the total amount of bonds, mortgages, or other securities of the publishing corporation. In item 11, if none, check the box. Use blank sheets if more space is required.
3. Be sure to furnish all circulation information called for in item 15. Free circulation must be shown in items 15d, e, and f.
4. If the publication had second-class authorization as a general or requester publication, this Statement of Ownership, Management, and Circulation must be published; it must be printed in any issue in October or, if the publication is not published during October, the first issue printed after October.
5. In item 16, indicate the date of the issue in which this Statement of Ownership will be published.
6. Item 17 must be signed.

Failure to file or publish a statement of ownership may lead to suspension of second-class authorization.